AB 1063 amends the Health and Safety Code to create a narrow, warrant‑based exception allowing the State Department of Public Health to release a newborn's physical blood test (residual blood spot) to law enforcement only when the warrant's stated objective is to obtain the DNA of a missing person suspected to be a victim of homicide, child abuse resulting in death, or manslaughter for comparison with the Department of Justice Missing Persons DNA Database and for upload for future identification. The bill also bars law enforcement from seeking warrants for other purposes—such as identifying suspects, building suspect databases, or proving guilt—and requires the California Biobank Program to report annually the number of search warrants received and disclosures made.
Why it matters: the measure legally brackets one of the thorniest intersections of public health and criminal investigation—access to newborn residual specimens—by carving a single, narrowly defined law‑enforcement use and creating a new transparency metric for the biobank. That combination changes operational responsibilities for public health agencies, maternity providers, and forensic partners while raising practical questions about judicial oversight, chain‑of‑custody, and parental expectations about specimen confidentiality.
At a Glance
What It Does
The bill permits the State Department of Public Health to release a newborn's physical blood test to law enforcement only in response to a search warrant whose purpose is to obtain a missing person's DNA suspected of being a homicide, child‑death abuse, or manslaughter victim and to upload the sample to the DOJ Missing Persons DNA Database. It explicitly prohibits warrants for other investigative ends, including suspect identification or building DNA databases.
Who It Affects
The primary actors affected are the State Department of Public Health and the California Biobank Program, hospitals and birth centers that collect newborn screening specimens, forensic laboratories and the Department of Justice Missing Persons DNA Database, and law enforcement agencies seeking DNA comparisons. Parents and researchers who rely on residual specimens for public health studies will also be affected indirectly through changes in policy and public trust.
Why It Matters
The bill sets a statutory boundary between public‑health specimen confidentiality and criminal‑investigative access while adding a new transparency obligation. Professionals in compliance, hospital risk, forensic labs, and public health must prepare new intake, legal‑review, and record‑keeping processes for warrant responses and track how this narrow exception will affect consent, trust, and specimen lifecycle management.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Newborn screening programs routinely collect tiny blood samples from infants to screen for inherited conditions and then retain leftover ‘‘residual’’ specimens for a range of public‑health uses. Historically, state law has treated information and specimens from hereditary disorder programs as strictly confidential.
AB 1063 keeps that baseline confidentiality but creates one tightly cabined pathway for law enforcement access: the State Department of Public Health may produce a physical newborn blood specimen only if served with a search warrant whose explicit objective is to obtain the DNA of a missing person believed to be a victim of homicide, fatal child abuse, or manslaughter, for purposes of comparison against, and upload to, the DOJ Missing Persons DNA Database.
The bill also sets express limits on law enforcement’s permissible uses: it prohibits seeking a warrant to determine whether a person is a criminal suspect, to build a DNA repository of suspects or nonsuspects, or to establish a person’s guilt. In practice that means the Department will need a process to review warrants for their stated purpose, to verify that requests fall inside the statutory exception, and to document any disclosures it makes.
The text gives the Department discretion—use of the word “may”—so the Department is not compelled to produce a specimen even when a warrant facially meets the criteria.To increase transparency, AB 1063 amends the California Biobank Program’s annual report to the Legislature to include two new counts: the number of search warrants received and the number of disclosures granted under the statute during the prior calendar year. Those tallies are additive to existing metrics the Biobank already reports.
Operationally, the change will require the Biobank and its hospital partners to maintain tighter chain‑of‑custody records, establish protocols for evidence transfer, and coordinate with forensic labs and the DOJ for database uploads.While the bill leaves many technical details to implementing agencies and the courts—such as the mechanics of judicial review, the evidentiary quality standard for specimens, or how parental destruction requests interact with law‑enforcement holds—it is definitive about allowable purposes. That clarity reduces ambiguity about whether newborn residuals are generally open to criminal inquiry, but it also creates discrete administrative burdens and potential points of contest between public‑health stewards and investigating authorities.
The Five Things You Need to Know
The statute applies specifically to a physical blood test taken from a newborn—i.e.
residual newborn screening specimens held by the California Biobank Program.
A release is allowed only when the search warrant’s objective is to obtain the DNA of a missing person suspected to be a victim of homicide, child abuse resulting in death, or manslaughter, and to compare and upload that DNA to the DOJ Missing Persons DNA Database.
The bill explicitly forbids law enforcement from requesting or obtaining a warrant for other purposes, including determining whether a person is a suspect, creating a DNA database of suspects or nonsuspects, or establishing guilt.
The department retains discretion—the law uses ‘‘may’’—so it is authorized but not compelled to comply with a warrant that meets the statutory conditions.
The California Biobank Program’s annual report must now include two new counts (for the prior calendar year): the number of search warrants received under the new section and the number of disclosures the Program granted.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Narrow warrant‑based exception for missing‑person DNA
This paragraph creates the substantive exception authorizing the State Department of Public Health to release a newborn’s physical blood specimen to law enforcement in response to a search warrant, but only when the warrant’s objective is to obtain the DNA of a missing person suspected to be a victim of homicide, fatal child abuse, or manslaughter and to compare it to, and upload it into, the DOJ Missing Persons DNA Database. Practically, this requires the Department to assess warrants against a specific purpose test rather than a broader evidentiary or investigative utility standard.
Express prohibitions on other warrant objectives
Subdivision (b) lists three explicit prohibitions: law enforcement cannot seek a warrant under this provision to determine whether a person is a suspect, to create a DNA database of suspects or nonsuspects, or to establish guilt. That language narrows permissible investigative uses and gives the Department a statutory basis to refuse warrants that are facially overbroad or that seek specimens for routine suspect identification or prosecution.
New reporting metrics for the California Biobank Program
The amendment adds two discrete reporting items to the Department’s annual newborn‑screening report: (1) the number of search warrants received by the California Biobank Program during the prior calendar year as described in the new section, and (2) the number of disclosures the Program made pursuant to such warrants. These are counted additions to the Biobank’s existing list of inventory, research, and destruction metrics and are designed to provide the Legislature with visibility into how often law enforcement seeks and obtains specimens.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Families of missing persons: The statute explicitly creates a legal route for investigators to obtain newborn specimens to help identify missing individuals who may be homicide or child‑death victims, potentially accelerating identification and closure.
- Missing‑persons investigators and forensic units: Investigators gain a narrowly tailored legal tool—when applicable—to compare newborn DNA to the DOJ Missing Persons DNA Database and to upload samples for future matches.
- Department of Justice Missing Persons DNA Database operators: The database could receive additional reference samples that improve match rates and downstream identifications, supporting the database’s public‑safety mission.
Who Bears the Cost
- State Department of Public Health / California Biobank Program: The Department must build legal‑review and intake workflows for warrants, maintain chain‑of‑custody and evidence‑handling protocols, and add tallying/reporting processes—none of which are funded by the bill text.
- Hospitals and birth centers that collect neonatal blood spots: Clinical providers will face operational changes for specimen transfer, temporary holds, or legal requests and may need to update consent materials and staff training.
- Research institutions and public‑health investigators: The addition of law‑enforcement access—even narrowly defined—risks eroding public trust in residual specimen stewardship, potentially reducing parental willingness to allow research use or increasing destruction requests.
Key Issues
The Core Tension
The central tension is between two legitimate public interests: enabling identification of missing persons (and providing closure to families) versus protecting the privacy and confidential stewardship of newborn genetic material; the bill solves for one narrow public‑safety use but leaves open how to prevent mission creep, ensure robust judicial oversight, and preserve trust in public‑health specimen programs.
Implementation raises multiple unanswered operational and legal questions. The bill requires a warrant with a specific objective but does not define procedural guardrails around judicial review or impose special evidentiary standards for specimens to be admissible in future proceedings.
Agencies will need to resolve how to authenticate and preserve neonatal blood spots so they meet forensic quality requirements, who pays for testing and transfer, and how to coordinate uploads with DOJ while preserving chain‑of‑custody and confidentiality for unrelated data in the Biobank.
Transparency is improved only at the aggregate level: the new report items are counts of warrants received and disclosures made, without mandated case details, timing, or outcomes. That limited reporting helps legislators track usage but leaves open whether the tally will be sufficient for oversight.
The statute also lacks an enforcement mechanism or remedies for improper disclosures (for example, if a court later finds a warrant was for an impermissible purpose), which means improper uses may be resolved in litigation rather than through statutory penalties. Finally, the bill does not address conflicts between a parent’s request to destroy specimens and subsequent law‑enforcement requests, creating a potential timing and legal‑priority question that implementing agencies will have to manage.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.